COVID-19: Impact in endothelial function and therapy with Mesenchymal Stromal Cells

The new pandemic of SARS-CoV-2 Betacoronavirus, has spread worldwide, and infected millions of individuals causing the disease denominated of COVID-19. Further on flu symptoms, due to the high tropism of virus, has most been observed in the COVID-19 pathophysiology: acute heart failure, thromboembo...

Full description

Bibliographic Details
Main Authors: Carla Longo de Freitas, Priscilla Yuri Okochi Alves da silva, Maria do Carmo Pinho Franco, Danilo Candido de Almeida
Format: Article
Language:English
Published: Unidad Central del Valle del Cauca 2021-12-01
Series:Magna Scientia UCEVA
Subjects:
Online Access:http://revistas.uceva.edu.co/index.php/magnascientia/article/view/2
Description
Summary:The new pandemic of SARS-CoV-2 Betacoronavirus, has spread worldwide, and infected millions of individuals causing the disease denominated of COVID-19. Further on flu symptoms, due to the high tropism of virus, has most been observed in the COVID-19 pathophysiology: acute heart failure, thromboembolism events, acute renal failure, neurological and liver damage, and multiple organ failure, with special attention to endothelial disfunction. Hence, elucidate whether virus target the endothelium is a crucial step to understand COVID-19 pathogenesis. However, the permissiveness of blood vessels during SARS-CoV-2 infection remains unclear, but regardless endothelial infection, the vascular disfunction may occurred in response to molecular inflammatory signaling triggered by immune cells that attempt to limit infection. Thus, alternative therapies using mesenchymal stromal cells (MSCs) can change this scenario and help critically ill patients. In this reflection, we attempt to discuss COVID-19 pathophysiology with impact in endothelial function and explore the applicability of MSC-based therapies as alternative treatment.  
ISSN:2805-6884
2805-6701